Biomea Fusion To Present Preclinical Data For BMF-500, An Investigational Oral Covalent FLT3 Inhibitor, At The 64th American Society Of Hematology Annual Meeting
BMF-500, an investigational third generation covalent FLT3 inhibitor, has demonstrated preclinically that it may be the most potent and selective inhibitor of FLT3 evaluated to date:
Greater Cytotoxicity: In acute
